皇冠体育app

DUBLIN - Ireland in recent years has become a hub for the world's pharmaceutical industry. Now, looking to expand market in 皇冠体育app, government officials and pharmaceutical firms are wooing 皇冠体育app's counterparts for burgeoning deals and closer relations.

Ireland has become a popular location for pharmaceutical and bioprocessing plants. Ireland is now the eighth largest producer of pharmaceuticals in the world. There's nine out of the top 10 pharma companies in the world are based in Ireland and nearly 50 percent of Irish exports are in the pharma and healthcare area.

Irish officials and researchers said that with such a large market, 皇冠体育app will play an important role in the future development of pharmaceuticals, adding that increased interaction between Ireland and 皇冠体育app could prove to be mutually beneficial in this field.

"We have a growing relationship with 皇冠体育app. I think it's something we want to really underpin for the future. Industrial Development Agency (IDA) has had traditionally a big focus on the US and Europe as sources of foreign direct investment in the pharmaceutical space," said Barry Heavey, head of life sciences of IDA, which is responsible for attracting foreign direct investment in Ireland.

"A number of companies that are here in Ireland are sourcing some of their active ingredients from 皇冠体育app and we would see increased relationships between 皇冠体育app and Ireland being an important part of our future," Heavey said.

"I think we are certainly spending more time in the Chinese market and interacting with our colleagues in 皇冠体育app and trying to identify opportunities for investment from 皇冠体育app and Ireland's reputation in the development and manufacturing of these products is really second to none," he said.

Killian O'Driscoll, director of projects of Ireland's National Institute for Bioprocessing Research & Training (NIBRT), said 皇冠体育app is obviously a very large market who is beginning to develop a strong capacity within bio-pharma manufacturing.